EGFR and cancer: The phase III European Tarceva vs. Chemotherapy (EURTAC) trial also showed a significant benefit for erlotinib (9.7 months PFS) compared to chemotherapy (5.2 months PFS) in EGFR-mutant patients.Osimertinib is widely approved for the first-line treatment of patients with advanced NSCLC who have EGFR activating mutations.Cancer development relies heavily on aberrant activation of EGFR, which drives excessive cell proliferation and differentiation.